Andere Sprachen Genenta Science S.p.A.

Aktien

A3C9EK

US36870W1009

GNTA

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:00 10.05.2024			% 5 Tage	% 1. Jan.
3.1 ^USD	-4.02%		-10.74%	-37.37%

06.05.	Genenta Science S.p.A. gibt die Ernennung neuer Vorstandsmitglieder bekannt	CI
08.04.	Genenta Science S.P.A. kündigt Rücktritt von Vorstandsmitgliedern an	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider	06.05.
Genenta Science S.p.A. Announces New Board Appointments	06.05.
Genenta Science S.P.A. Announces Resignation of Board Members	08.04.
Genenta Science S p A : NOTICE OF CALL OF THE ORDINARY AND EXTRAORDINARY SHAREHOLDERS’ MEETING - Form 6-K	02.04.
Genenta Science S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023	29.03.
Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors	08.02.
Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors	08.02.
Genenta Science Demonstrated Reprogramming of the Tumor Microenvironment in Gbm Patients, Paving the Way for Innovative Treatments of Solid Tumors	08.02.
Sandoz to Acquire Cimerli Business from Coherus for $170 Million	22.01.
Genenta Science S p A : Consolidated Statements of Operations and Comprehensive Loss - Form 6-K	20.10.23
Genenta Science S.p.A. Reports Earnings Results for the Half Year Ended June 30, 2023	20.10.23
Genenta to Present at Upcoming Scientific and Investor Conferences	06.09.23
Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments	28.07.23
Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments	28.07.23
Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments	28.07.23
The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma	29.06.23
Health Care Stocks Support American Depositary Receipts of European Equities	16.06.23
Genenta to Provide Update on Lead Product Temferon™	16.05.23
Genenta Science S p A : NOTICE OF CALL OF THE ORDINARY AND EXTRAORDINARY SHAREHOLDERS’ MEETING - Form 6-K	10.05.23
Genenta Science S p A : Effectiveness of the Amended and Restated OSR License Agreement - Form 6-K	01.05.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Genenta Science S.p.A.

Aktien

A3C9EK

US36870W1009

GNTA

Andere Sprachen

Filter